Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer

Szatkowski, Wiktor; Muzykiewicz, Konrad; Jasiówka, Marek; Karolewski, Kazimierz; Kojs, Z; Klimek, Małgorzata; Blecharz, Paweł

doi:10.5603/gp.2016.0019

Cited by 3 publications

(5 citation statements)

References 15 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among these included articles, 50 studies 6,7,9–12,18–61 evaluated the relationship between patients with BRCAms and the clinical features of ovarian cancer, and 22 studies 6,7,9,11,12,21,28,32,38–40,44,45,48,49,52,53,58–60,62,63 evaluated the relationship between patients with BRCAms and surgical outcomes. Also, 48 studies ,6–12,18,21,26–30,32–41,44–49,52–54,57–71 evaluated the relationship between BRCAms and the prognosis of ovarian cancer. The quality assessment showed that the NOS score of each study was not less than 7, indicating that the methodological quality was generally good.…”

Section: Resultsmentioning

confidence: 99%

“…Among these included articles, 50 studies 6,7,9-12,18-61 evaluated the relationship between patients with BRCAms and the clinical features of ovarian cancer, and 22 studies 6,7,9,11,12,21,28,32,[38][39][40]44,45,48,49,52,53,[58][59][60]62,63 evaluated the relationship between patients with BRCAms and surgical outcomes. Also, 48 studies , [6][7][8][9][10][11][12]18,21,[26][27][28][29][30][32][33][34][35][36][37][38][39][40][41][44][45][46][47]…”

Section: Discussionmentioning

confidence: 99%

“…Twenty-two studies 6,7,9,11,12,21,28,32,[38][39][40]44,45,48,49,52,53,[58][59][60]62,63 provided a comparison of surgical outcomes between BRCAm carriers and noncarriers. Satisfactory tumor cell reduction was determined according to the size of residual tumor lesions during tumor reduction, the diameter of the tumors measured <1 cm was satisfactory, and a diameter >1 cm was unsatisfactory.…”

Section: The Association Between the Presence Of Brcams And Surgical ...mentioning

confidence: 99%

“…Twenty studies 6,7,11,26,29,30,41,45,47,48,57,59,[61][62][63][64]67,68,70,71 provided OS data of patients with BRCA1 mutations. Heterogeneity was observed among the 20 studies (I 2 = 67%); therefore, a random effects model was used.…”

Section: Meta-analysis Of Brca1 Mutationsmentioning

confidence: 99%

See 3 more Smart Citations

Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta‐analysis

Wang

Ren

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim This meta‐analysis was conducted to evaluate the impact of BRCA mutations on survival outcomes of ovarian cancer patients and assess whether the BRCA status was an independent predictor of complete cytoreduction. Methods We searched the PubMed, Cochrane, EMBASE, Scopus, Web of Science, and Google Scholar databases for studies that evaluated the associations among BRCA mutations, ovarian cancer survival and surgical cytoreduction before August 2021 based on specific inclusion and exclusion criteria. Results We identified 61 articles that compared the clinical features, survival outcomes, and optimal surgical cytoreduction rates between BRCA‐positive patients and BRCA‐negative patients. The results showed that BRCA mutation carriers were diagnosed with ovarian cancer at a younger age than the age at which nonmutation carriers were diagnosed. In addition, BRCA mutation carriers were more likely to be in the International Federation of Gynecology and Obstetrics (FIGO) stage III‐IV, and the pathological grade was commonly grade 3. The pathological type of BRCA mutation carriers was more likely to be high‐grade serous carcinoma. Patients with BRCA mutations had higher response rates to platinum‐based chemotherapy than the noncarriers. However, patients in both groups had equivalent rates of surgical cytoreduction, and BRCA‐positive patients had longer overall survival (OS) time (HR = 0.65; 95% confidence interval [CI]: 0.59, 0.73; p < 0.001) and longer progression‐free survival (PFS) (HR = 0.72; 95% CI: 0.63, 0.82; p < 0.001). Conclusion BRCA mutations appear to be associated with improved OS and PFS in patients with ovarian cancer. However, we did not find any difference in the surgical resection rate between participants in the two groups.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: The Association Between the Presence Of Brcams And Surgical ...mentioning

confidence: 99%

Section: Meta-analysis Of Brca1 Mutationsmentioning

confidence: 99%

See 2 more Smart Citations

Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta‐analysis

Wang

Ren

et al. 2022

J of Obstet and Gynaecol

View full text Add to dashboard Cite

show abstract

“…The lack of a sufficiently accurate screening test and the non-specific character of symptoms in an early stage impede the diagnosis and thus decrease the chance for survival [ 4 ]. Screening tests do not even include women with diagnosed mutation in BRCA1 and BRCA2 genes [ 5 , 6 ]. Only 20–30% of cases are diagnosed in stage I and II, and the remaining 70% cases are diagnosed in stage III and IV [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Survival rates among women with ovarian cancers diagnosed in the area of Podkarpacie province in the years 1990–2015

Radziszewska

Karczmarek-Borowska

Wójcik³

et al. 2018

View full text Add to dashboard Cite

Aim of the studyThe objective of the study was to analyse the survival rate of women with malignant ovarian tumours in the years 1990–2015 in the Podkarpacie province.Material and methodsThe database used for calculations covered 2399 cancer incidences verified at the end of 2014. The estimated relative survival rates were calculated by means of the Hakulinen method.ResultsThe number of recorded cases amounted to 196 in 2015 and was higher by 86.7% than in 1990. The rates of one-year, three-year, and five-year survival was 72.5%, 51.2%, and 42.4%, respectively.ConclusionsSurvival rates of women with ovarian cancer in the Podkarpacie province are comparable to survivals calculated for the entire Poland region. Despite the low risk factor, women suffering from ovarian adenocarcinoma have lower survival rates than others, and as many as 42.5% of patients with adenocarcinoma were diagnosed in stage IV. Steps aimed at improvement of detectability of ovarian cancers in the earliest possible stage should be taken. This should increase survival rates in each age group.

show abstract

DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies

Mirza-Aghazadeh-Attari

Ostadian

Saei

et al. 2019

DNA Repair

View full text Add to dashboard Cite

Comparison of effectiveness of treatment of patients with sporadic and germline BRCA1-related ovarian cancer

Cited by 3 publications

References 15 publications

Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta‐analysis

Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta‐analysis

Survival rates among women with ovarian cancers diagnosed in the area of Podkarpacie province in the years 1990–2015

DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies

Contact Info

Product

Resources

About